Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see the safety and activity of using pasireotide, everolimus
and radioembolization (Selective Internal Radioembolization Therapy-SIRT) in the treatment of
neuroendocrine tumors (carcinoid) that has spread to the liver. Both everolimus or
radioembolization are considered "standard of care" regimens in patients with liver lesions
from neuroendocrine tumors. However, the use of the combination of everolimus and
radioembolization has not been formally evaluated in the setting of a clinical trial.
Pasireotide is a medication that is intended to block the hormonal secretions from the
neuroendocrine tumors.
This study is divided into two parts. In the first part, the aim of the study is to determine
the safety of combining everolimus, pasireotide, and radioembolization. For this part of the
study the investigators will enroll up to 18 patients. After the investigators confirm the
safety of the combination, they will conduct the second part of the study which will focus on
evaluating the effectiveness of the combination. For this part of the study the investigators
intend to enroll a total of 37 patients.